Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 4 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar pchop123 (79.59) Submitted: 4/24/2013 9:45:48 AM : Outperform Start Price: $38.38 ACOR Score: -4.82

just a pause before continuing UP

Featured Broker Partners


Advertisement